Four Decades for Justice
Cravath represented Mylan N.V. in connection with its US$1 billion Rule 144A/Reg. S investment grade senior debt offering. Mylan N.V. is a leading global pharmaceutical company that develops, licenses, manufactures, markets and distributes generic, branded generic and specialty pharmaceuticals. The notes will be listed on the Irish Stock Exchange. The transaction closed on December 9, 2015.
The Cravath team included partner William V. Fogg and associates Benjamin S. Persina and Douglas C. Dolan on securities matters and partner J. Leonard Teti II and associate Kiran Sheffrin on tax matters. Jin‑Kyu Baek also worked on securities matters.
Celebrating 200 years of partnership. In 2019, we celebrated our bicentennial. Our history mirrors that of our nation. Integral to our story is our culture.
Attorney Advertising. ©2024 Cravath, Swaine & Moore LLP.